Kimberly-Clark's Risky Bet on Tylenol Amid Political Heat

Kimberly-Clark, a giant in consumer goods, has made a bold move by acquiring Kenvue, the company behind Tylenol. However, Wall Street wasn't pleased. The stock took a massive hit, the worst since the 1987 crash, dropping by 15%.

Why the Risk?

Kimberly-Clark is betting that Tylenol can handle the heat. President Trump and Health Secretary Kennedy have been targeting Tylenol, making unproven claims about its link to autism. It's a risky bet for Kimberly-Clark.

Novo Nordisk's Advertising Strategy

Meanwhile, Novo Nordisk has been spending big on ads—about $7.5 million on weight loss searches. Even though their drug, Ozempic, isn't approved for weight loss, they're getting a lot of website visits. A clever way to bypass advertising rules.

Pfizer's Legal Battle

Pfizer isn't happy. They've sued Novo Nordisk and Metsera, a startup, accusing Novo of blocking competition in the weight-loss market. Pfizer has filed lawsuits to stop Novo from acquiring Metsera. Novo and Metsera call Pfizer's claims nonsense.

Telehealth and the GLP-1 Trend

Telehealth companies are jumping on the GLP-1 bandwagon, offering microdosed versions of these drugs. Celebrities like Rebel Wilson and Andy Cohen are promoting these programs. But is this trend really helpful for patients?